Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC16A1 | P53985 | 20/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.48 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.48 |
| ▸ | CAMK2B | Q13554 | 1/20 | 0.48 |
| ▸ | HIPK4 | Q8NE63 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6726116 | 0.81 | SLC16A1 (0.49) | SLC16A1CYP2C9MAPKAPK2CAMK2BHIPK4 | |
| SCHEMBL6724402 | 0.79 | SLC16A1 (0.75) | SLC16A1CYP2C9CYP3A4 | |
| SCHEMBL6726613 | 0.78 | SLC16A1 (0.47) | SLC16A1CYP2C9MAPKAPK2CAMK2BHIPK4 | |
| SCHEMBL7007249 | 0.78 | SLC16A1 (0.47) | SLC16A1CYP2C9MAPKAPK2CAMK2BHIPK4 | |
| SCHEMBL6724379 | 0.77 | SLC16A1 (0.44) | SLC16A1CYP2C9MAPKAPK2CAMK2BHIPK4 | |
| SCHEMBL7011500 | 0.75 | SLC16A1 (0.49) | SLC16A1CYP2C9MAPKAPK2CAMK2BHIPK4 | |
| SCHEMBL6721723 | 0.74 | PDE2A (0.45) | SLC16A1CYP2C9MAPKAPK2CAMK2BHIPK4 | |
| SCHEMBL6726095 | 0.73 | SLC16A1 (0.41) | SLC16A1CYP2C9MAPKAPK2CAMK2BHIPK4 | |
| SCHEMBL6733683 | 0.69 | SLC16A1 (0.54) | SLC16A1CYP2C9CYP3A4 | |
| SCHEMBL6725102 | 0.69 | SLC16A1 (0.53) | SLC16A1CYP2C9CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040014634-A1 | Thieno[2,3-d]pyrimidinediones and their use as pharmaceuticals | ASTRAZENECA AB (SE) | 2004-01-22 | — | — | US | claimed |
| EP-1280806-A1 | THIENO 2,3-d]PYRIMIDINEDIONES AND THEIR USE AS PHARMACEUTICALS | AstraZeneca AB (SE) | 2003-02-05 | — | — | EP | claimed |
| WO-2001083489-A1 | THIENO[2,3-d]PYRIMIDINEDIONES AND THEIR USE AS PHARMACEUTICALS | ASTRAZENECA AB (SE) | 2001-11-08 | — | — | WO | claimed |
| US-20040014634-A1 | Thieno[2,3-d]pyrimidinediones and their use as pharmaceuticals | ASTRAZENECA AB (SE) | 2004-01-22 | — | — | US | disclosed |
| EP-1280806-A1 | THIENO 2,3-d]PYRIMIDINEDIONES AND THEIR USE AS PHARMACEUTICALS | AstraZeneca AB (SE) | 2003-02-05 | — | — | EP | disclosed |
| WO-2001083489-A1 | THIENO[2,3-d]PYRIMIDINEDIONES AND THEIR USE AS PHARMACEUTICALS | ASTRAZENECA AB (SE) | 2001-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014634-A1 | Thieno[2,3-d]pyrimidinediones and their use as pharmaceuticals | DPYD, TYMP, TYMS | SLC16A1 4584/4885CYP2C9 126/4885MAPKAPK2 2918/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.